Literature DB >> 11445440

The isoprostanes in biology and medicine.

D Praticò1, J A Lawson, J Rokach, G A FitzGerald.   

Abstract

Isoprostanes are a new class of lipids, isomers of the conventional enzymatically derived prostaglandins, which are produced in vivo primarily by a free radical-catalyzed peroxidation of polyunsaturated fatty acids. F2-isoprostanes, isomers of the enzyme-derived prostaglandin F2alpha, are the most studied species, but analogous isomers of other prostaglandins and leukotrienes have been described. Because of their mechanism of formation, specific structural features that distinguish them from other free radical-generated products and chemical stability, they can provide a reliable index for the oxidant component of several diseases in vivo. Consistent data suggest that formation of F2-isoprostanes is altered in a variety of clinical settings putatively associated with oxidant stress. Moreover, measurement of F2-isoprostanes might provide a sensitive biochemical basis for dose-selection in studies of natural and synthetic antioxidants. Finally, some F2-isoprostanes possess potent biological activities in vitro and in vivo, suggesting that they may also act as mediators of the cellular effects of oxidative stress.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11445440     DOI: 10.1016/s1043-2760(01)00411-8

Source DB:  PubMed          Journal:  Trends Endocrinol Metab        ISSN: 1043-2760            Impact factor:   12.015


  34 in total

1.  Renal sodium transporter/channel expression and sodium excretion in P2Y2 receptor knockout mice fed a high-NaCl diet with/without aldosterone infusion.

Authors:  Yue Zhang; Raelene Listhrop; Carolyn M Ecelbarger; Bellamkonda K Kishore
Journal:  Am J Physiol Renal Physiol       Date:  2010-12-29

2.  Urinary F2-isoprostanes, obesity, and weight gain in the IRAS cohort.

Authors:  Dora Il'yasova; Frances Wang; Ivan Spasojevic; Karel Base; Ralph B D'Agostino; Lynne E Wagenknecht
Journal:  Obesity (Silver Spring)       Date:  2011-09-29       Impact factor: 5.002

3.  Simultaneous HPLC-MS-MS quantification of 8-iso-PGF(2alpha) and 8,12-iso-iPF(2alpha) in CSF and brain tissue samples with on-line cleanup.

Authors:  Magdalena Korecka; Christopher M Clark; Virginia M-Y Lee; John Q Trojanowski; Leslie M Shaw
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2010-07-01       Impact factor: 3.205

4.  Blood and urine 8-iso-PGF2α levels in babies of different gestational ages.

Authors:  Sitao Li; Hu Hao; Ping Zhou; Ping Ming Gao; Xin Xiao
Journal:  Int J Clin Exp Med       Date:  2014-12-15

Review 5.  The role of biomarkers in clinical trials for Alzheimer disease.

Authors:  Leon J Thal; Kejal Kantarci; Eric M Reiman; William E Klunk; Michael W Weiner; Henrik Zetterberg; Douglas Galasko; Domenico Praticò; Sue Griffin; Dale Schenk; Eric Siemers
Journal:  Alzheimer Dis Assoc Disord       Date:  2006 Jan-Mar       Impact factor: 2.703

6.  Obesity, age, and oxidative stress in middle-aged and older women.

Authors:  Tsogzolmaa Dorjgochoo; Yu-Tang Gao; Wong-Ho Chow; Xiao-Ou Shu; Gong Yang; Quiyin Cai; Nathaniel Rothman; Hui Cai; Honglan Li; Xinqing Deng; Martha J Shrubsole; Harvey Murff; Ginger Milne; Wei Zheng; Qi Dai
Journal:  Antioxid Redox Signal       Date:  2011-03-21       Impact factor: 8.401

Review 7.  Prostanoid signaling: dual role for prostaglandin E2 in neurotoxicity.

Authors:  Dejan Milatovic; Thomas J Montine; Michael Aschner
Journal:  Neurotoxicology       Date:  2011-03-03       Impact factor: 4.294

8.  Longitudinal CSF isoprostane and MRI atrophy in the progression to AD.

Authors:  M J de Leon; L Mosconi; J Li; S De Santi; Y Yao; W H Tsui; E Pirraglia; K Rich; E Javier; M Brys; L Glodzik; R Switalski; L A Saint Louis; D Pratico
Journal:  J Neurol       Date:  2007-11-14       Impact factor: 4.849

9.  Modulation of nuclear factor-kappa B activity by indomethacin influences A beta levels but not A beta precursor protein metabolism in a model of Alzheimer's disease.

Authors:  Syaun Sung; Hengxuan Yang; Kunihiro Uryu; Edward B Lee; Lei Zhao; Diana Shineman; John Q Trojanowski; Virginia M-Y Lee; Domenico Praticò
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

10.  Hyperbaric treatment for children with autism: a multicenter, randomized, double-blind, controlled trial.

Authors:  Daniel A Rossignol; Lanier W Rossignol; Scott Smith; Cindy Schneider; Sally Logerquist; Anju Usman; Jim Neubrander; Eric M Madren; Gregg Hintz; Barry Grushkin; Elizabeth A Mumper
Journal:  BMC Pediatr       Date:  2009-03-13       Impact factor: 2.125

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.